Helical Fusion Announces Construction Site for Phase 1 of “Helix HARUKA,” Marking Transition to Manufacturing and Assembly of Fusion Hardware
16.3.2026 14:00:00 CET | Business Wire | Press release
Advances one of Japan’s leading public-private partnership initiatives for fusion commercialization with NIFS and industrial partners
Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; “Helical Fusion”), a Japanese fusion energy company advancing the Helix Program and developing the Helical Stellarator for commercial fusion power plants, announced the construction site for Phase 1 of Helix HARUKA, its Integrated Demonstration Device.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316066384/en/
Concept image of Helix HARUKA, Helical Fusion’s integrated demonstration device
Phase 1—the magnet demonstration phase—will be built in a dedicated workspace for the joint research group formed by Helical Fusion and the National Institute for Fusion Science (NIFS), located on the NIFS campus. Helical Fusion has already begun manufacturing phase and site build-out, with the aim of conducting coil current (energization) tests in 2027.
It also highlights Helical Fusion’s role in leading a “Japan-style public–private partnership (PPP)” for fusion commercialization. By bringing together NIFS’s world-class research foundation and infrastructure with Helical Fusion’s private-sector system integration and the manufacturing capabilities of industrial partners, the company is building a tightly coupled build-and-test loop.
In Phase 1, Helical Fusion will assemble a non-planar helical high-temperature superconducting (HTS) magnet and conduct current tests to validate the magnet’s performance as a system under expected operating conditions. In magnetic-confinement fusion, the magnet is a core technology that fundamentally shapes performance, reliability, and economics. As international competition intensifies, Helical Fusion is advancing a development model that connects research excellence with manufacturing execution and hardware integration.
Overview of Demonstration Phases within the Helix Program
1) Helix HARUKA — Phase 1 (Magnet Demonstration)
Purpose: Current-testing of a non-planar helical HTS magnet system.
Location: Dedicated space for the joint research group on the NIFS campus.
2) Helix HARUKA — Phase 2 (Integrated Demonstration)
Purpose: Integrated demonstration of key enabling technologies—including the HTS magnet and the blanket/divertor—together with a key milestone of the program: demonstrating sustained high-temperature plasma operation for durations sufficient to underpin an engineering outlook toward steady-state power-plant operation. This is intended to establish technical confidence for the first power-generating unit, Helix KANATA.
Note: No power generation will be conducted in Phase 2.
Location: Not disclosed.
3) Helix KANATA (First Power-Generating Unit)
Purpose: Achieve “practical power generation,” including net-electric operation, steady-state operation, and maintainability demonstrations.
Location: Not disclosed.
Background
Collaboration with NIFS
NIFS is a leading public research institution driving helical stellarator fusion research, operating the Large Helical Device (LHD), one of the world’s foremost large-scale plasma experimental facilities for the stellarator approach. Through LHD, NIFS has accumulated key operating know-how for long-duration operation, including sustaining plasma for 3,268 seconds (54 minutes 28 seconds), alongside advances in plasma stability control and management of heat and particle loads. NIFS is also recognized for deep expertise in fusion reactor engineering design
Helical Fusion was founded in 2021 as a spin-out leveraging research outcomes from NIFS. Since 2024, Helical Fusion and NIFS have operated under a formal joint research framework, collaborating on key technologies including HTS magnet systems and blanket/divertor systems. By locating Phase 1 at the dedicated joint workspace on the NIFS campus, Helical Fusion will more tightly connect research and hardware buildout—accelerating engineering integration.
This structure is emerging as a leading example of how Japan can commercialize fusion: a national research institution providing deep scientific and engineering knowledge, a startup driving speed and plant-level system integration, and industrial partners contributing manufacturing and execution capability. Helical Fusion believes this public–private model can become a distinctive strength of Japan’s fusion industry.
About Helical Fusion
Helical Fusion is pursuing the commercialization of fusion energy through the Helical Stellarator. Japan’s helical approach has been advanced through decades of R&D across national universities and public research institutions, and is regarded as well-suited to the requirements of commercial power generation. Building on that foundation, Helical Fusion is executing the Helix Program, which targets: (i) completion of standalone demonstrations of two major development elements—HTS magnets and the blanket/divertor—during the 2020s; and (ii) integrated demonstration via Helix HARUKA and the achievement of commercially viable power generation with Helix KANATA during the 2030s.
Reference: https://www.youtube.com/watch?v=XMXTviHZe6w
Company Overview
Company Name: Helical Fusion Co., Ltd.
Head Office: Chuo-ku, Tokyo, Japan
CEO: Takaya Taguchi
Business: Design and development of the Helical Stellarator
View source version on businesswire.com: https://www.businesswire.com/news/home/20260316066384/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release
Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom